Real-world applications and validated results from our in-silico platform
Expert-grade therapy response prediction using CrisPRO.ai genome-scale language model. We quantify mutation disruption in critical cancer pathways (RAS/MAPK and TP53) to predict patient sensitivity vs resistance — with live, transcript-aware scoring and strict data hygiene.